Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 May;6(3):e414.
doi: 10.1002/edm2.414. Epub 2023 Mar 2.

Assessing non-adjunctive CGM safety at home and in new markets (ANSHIN)

Christy Chao  1 , Sarah B Andrade  1 , Simon Bergford  2 , Peter Calhoun  2 , John B Welsh  1 , Tomas C Walker  1 ; ANSHIN Study Group
Affiliations
Randomized Controlled Trial

Assessing non-adjunctive CGM safety at home and in new markets (ANSHIN)

Christy Chao et al. Endocrinol Diabetes Metab. 2023 May.

Abstract

Introduction: Continuous glucose monitoring (CGM) can guide treatment for people with type 1 (T1D) and type 2 diabetes (T2D). The ANSHIN study assessed the impact of non-adjunctive CGM use in adults with diabetes using intensive insulin therapy (IIT).

Materials and methods: This single-arm, prospective, interventional study enrolled adults with T1D or T2D who had not used CGM in the prior 6 months. Participants wore blinded CGMs (Dexcom G6) during a 20-day run-in phase, with treatment based on fingerstick glucose values, followed by a 16-week intervention phase and then a randomized 12-week extension phase with treatment based on CGM values. The primary outcome was change in HbA1c. Secondary outcomes were CGM metrics. Safety endpoints were the number of severe hypoglycaemic (SH) and diabetic ketoacidosis (DKA) events.

Results: Of the 77 adults enrolled, 63 completed the study. Those enrolled had mean (SD) baseline HbA1c of 9.8% (1.9%), 36% had T1D, and 44% were ≥65 years old. Mean HbA1c decreased by 1.3, 1.0 and 1.0 percentage points for participants with T1D, T2D or age ≥65, respectively (p < .001 for each). CGM-based metrics including time in range also improved significantly. SH events decreased from the run-in period (67.3 per 100 person-years) to the intervention period (17.0 per 100 person-years). Three DKA events unrelated to CGM use occurred during the total intervention period.

Conclusions: Non-adjunctive use of the Dexcom G6 CGM system improved glycaemic control and was safe for adults using IIT.

Keywords: blood glucose self-monitoring; glycaemic control; glycated haemoglobin.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Flowchart of clinic visits and study completion.
FIGURE 2
FIGURE 2
Scatter plot for HbA1c (%) at end of phase one versus baseline.
See this image and copyright information in PMC

References

    1. Karter AJ, Ackerson LM, Darbinian JA, et al. Self‐monitoring of blood glucose levels and glycemic control: the northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111(1):1‐9. - PubMed
    1. Price D, Walker T. The rationale for continuous glucose monitoring‐based Diabetes treatment decisions and non‐adjunctive continuous glucose monitoring use. Eur Endocrinol. 2016;12(1):24‐30. - PMC - PubMed
    1. Pettus J, Price DA, Edelman SV. How patients with type 1 Diabetes translate continuous glucose monitoring data into Diabetes management decisions. Endocr Pract. 2015;21(6):613‐620. - PubMed
    1. Akturk HK, Dowd R, Shankar K, Derdzinski M. Real‐world evidence and glycemic improvement using Dexcom G6 features. Diabetes Technol Ther. 2021;23(S1):S21‐S26. - PMC - PubMed
    1. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371‐378. - PubMed

Publication types